Keynote SeriesBioPharm International and Pharmaceutical Technology are sponsoring a Keynote Series discussion on bioprocessing challenges on the INTERPHEX 2016 Exhibit Hall Innovation Stage. Admission is free to any attendee with an exhibit hall pass.
Tuesday, April 26, 10:15 am to 11:45 am
Overcoming Bottlenecks in Biopharmaceutical Development
In a panel discussion, industry experts will discuss how technology advances are addressing challenges in biopharmaceutical development including quality control of raw materials, implementation of single-use technologies, process monitoring, and downstream purification.
Panelists:
Marian L. McKee, PhD, Director, US Development Services, MilliporeSigma
Mike Goodwin, Director of R&D, SUT, Thermo Fisher Scientific
Alex Perieteanu, PhD, Director, Biopharmaceutical Services - Life Sciences, SGS Mississauga
Elizabeth Goodrich, Director of Applications Engineering, MilliporeSigma
To register: http://www.interphex.com/pharmtech
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Filter Sizing for Process Optimization in Life Sciences Sterile Filtration
April 24th 2025Bench-scale filterability studies play a critical role in optimizing sterile filtration in biopharmaceutical manufacturing. By guiding the selection and sizing of filters, these studies help streamline processes, improve scalability, and reduce costs. Through data-driven case studies, this paper highlights how the strategic use of pre-filters and membrane materials can maximize throughput and minimize filter fouling.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.